Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol sees Medarex acquisition as a way to expand its immunology and oncology pipeline in preparing for Plavix generics in 2012.
Advertisement

Related Content

Don't Call It An Asset Swap: Bristol Expands Rights To Anti-PD-1 Antibody In No-Cash Transaction With Ono
Don't Call It An Asset Swap: Bristol Expands Rights To Anti-PD-1 Antibody In No-Cash Transaction With Ono
Don't Call It An Asset Swap: Bristol Expands Rights To Anti-PD-1 Antibody In No-Cash Transaction With Ono
BMS Adds To String Of Pearls: $470 Mil. Deal With French Biotech Brings Innate Immunity Approach Into Its R&D Pipeline
Ipilimumab Data Impress, But Vaccine Control Could Complicate Review
AstraZeneca/Bristol's Diabetes Drug Onglyza Cleared
Bristol's Poker Game: Doubling Down On Research
Bristol's Poker Game: Doubling Down On Research
BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion
Bristol Rebuilds Oncology Business: Smart Work at FDA Helps

Topics

Advertisement
UsernamePublicRestriction

Register

PS069734

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel